Investor Relations

IceCure is transforming healthcare by bringing the choice of advanced minimally invasive cryoablation treatment options for benign and malignant tumors to women's health and interventional oncology.

Latest News

IceCure Medical to Report Third Quarter 2024 Financial & Operational Results on November 26, 2024

View Press Release

IceCure's ProSense® Chosen for Breast Cryoablation Study Led by the Prestigious European Institute of Oncology with Sponsorship from the Italian Ministry of Health

View Press Release

FDA Advisory Panel Votes in Favor of IceCure's ProSense® Cryoablation Benefit-Risk Profile in Early-Stage Low Risk Breast Cancer

View Press Release
Company Presentation

Latest Presentation

Company Presentation

August 2024 Fact Sheet

Fact Sheet

August 2024 Fact Sheet

Upcoming Event

Q3 2024 Results Conference Call

Company Overview

IceCure is transforming healthcare by bringing the choice of advanced minimally invasive cryoablation treatment options for benign and malignant tumors to women's health and interventional oncology. Its liquid-nitrogen based systems use ultra cold temperatures to destroy tumors by freezing them. Supported by clinical experience across multiple areas of cancer care, IceCure is opening the door for quick, convenient office-based and CT room procedures. Cryoablation - It's your choice.

Latest Financial Results

Q2 2024

Quarter Ended Jun 30, 2024

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2023

Stock Snapshot

IR Contacts

Headquarters

IceCure Medical Ltd.
7 Ha’Eshel Street
PO Box 3163
Caesarea 3079504
Israel
T: +972-4-623-0333
F: +972-4-623-0222
investors@icecure-medical.com

Investor Relations

EVC Group
Michael Polyviou
Todd Kehrli
T: +1-732-933-2755
investors@icecure-medical.com
https://www.evcgroup.com

Transfer Agent

VStock Transfer, LLC
18 Lafayette Place
Woodmere, NY 11598
T: 212-828-8436
F: 646-536-3179
info@vstocktransfer.com